Clincial Study Patient Recruitment and Site Engagement

A campaign to support a randomized, double-blind, placebo-controlled, active comparator Phase 2/3 study of an investigational drug in combination with trastuzumab, ramucirumab, and paclitaxel in subjects with previously treated, locally-advanced unresectable or metastatic HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC).

This study was conducted to see if tucatinib in combination with trastuzumab, ramucirumab and paclitaxel was more effective than ramucirumab and paclitaxel to treat HER2-positive (HER2+) gastroesophageal cancer. This study also evaluated the side effects of this combination of drugs. Study treatment were given in 28-day cycles.